Capricor Therapeutics, Inc.
CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscā¦ read more
Healthcare
Biotechnology
18 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$27.81
Price+6.19%
$1.62
1Y
Price
Market Cap
$1.271b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$11.131m
-50.0%
1y CAGR+275.1%
3y CAGR+441.8%
5y CAGREarnings
-$81.990m
-102.6%
1y CAGR-53.7%
3y CAGR-51.5%
5y CAGREPS
-$1.80
-56.5%
1y CAGR-21.8%
3y CAGR-25.3%
5y CAGRBook Value
$83.867m
$126.438m
Assets$42.571m
Liabilities$14.543m
DebtDebt to Assets
11.5%
-0.2x
Debt to EBITDAFree Cash Flow
-$44.677m
-7.6%
1y CAGR-644.5%
3y CAGR-456.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company